In adults with atrial fibrillation and type 2 diabetes, tirzepatide use was associated with a lower risk of any stroke than other GLP-1 receptor agonists; the absolute difference was 2.1 percentage points at one year.
In plain wordsIn adults with atrial fibrillation and type 2 diabetes, tirzepatide use was linked to fewer strokes than other GLP-1 drugs.
- Peptide
- Tirzepatide
- Outcome
- DecreaseAny stroke
- Study
n = 28,236
- Comparator
- Other GLP-1 receptor agonists
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- Absolute difference in stroke risk
- 2.1 percentage points
- 1 year
Source sentences
Here we show that, among 14,118 matched pairs of adults initiating tirzepatide or another glucagon-like peptide-1 receptor agonist, tirzepatide use was associated with lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and death from any cause.
3 context sentences(design, population, supporting numbers)
The absolute difference in stroke risk was 2.1 percentage points at one year, and the absolute difference in mortality was 6.2 percentage points.
Patients with atrial fibrillation and type 2 diabetes remain at high risk of stroke despite anticoagulation and glucose-lowering treatment.
We examined whether tirzepatide was associated with lower cerebrovascular risk than established glucagon-like peptide-1 receptor agonists in a retrospective cohort from a large international federated electronic health-record network.